2seventy bio v Johnson & Johnson (CFI, 2026-09-23)
| Date | 2026-09-23 |
|---|---|
| Court | CFI |
| Division | Brussels (BE) Local Division |
| Type of action | Infringement Action |
| Case number(s) | UPC_CFI_29/2026 |
| Registry reference | UPC-CFI-0000029/2026 |
| Parties | 2seventy bio, Inc. v. Johnson & Johnson, Janssen Biotech, Inc., Janssen Pharmaceuticals Inc., Janssen-Cilag International NV, Janssen Pharmace… |
| Language | English |
Official headnote
When assessing an application to produce evidence, the Court should assess the plausibility of the underlying claims at that stage of the proceedings. (headnote 6 of 7) The condition of 'prior notice' in Article 47(2) or (3) UPCA should be assessed by the Court when the action is brought. (headnote 7 of 7)
Official decision (PDF) · UPC registry entry
Case timeline
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Decisions in the same proceedings
Going further
Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.
Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.
Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).